

**NICE PUBLIC HEALTH PROGRAMME GUIDANCE
Alcohol- use disorders (prevention)**

1st meeting of the Programme Development Group

Thursday 4th September 2008

Floor 24, City Tower, Piccadilly Plaza, Manchester M1 4BD

Final Minutes

Attendees:	<p>PDG Members Jane Benanti (JB), John Dervan (JD), Paul Edmondson-Jones (PE), Vivienne Evans (VE), Jayne Gosnall (JG), Nick Heather (NH), Sauid Ishaq (SI), Eileen Kaner (EK), Anne Ludbrook. (AL) Harshad Mistri (HM), Trevor McCarthy (TM), Jim McCambridge (JMc), Paul McArdle (PMc),Lynn Owens (LO), Ian Treasure (IT).</p> <p>NICE Andrew Hoy (AH), Dylan Jones (DJ), James Jagroo (JJ), Julian Lewis (JL), Antony Morgan (AM), Patricia Mountain (PM), Bhash Naidoo (BN), Linda Sheppard (LS).</p> <p>Contractors - SchARR Rachel Jackson (RJ), Jim Chilcott (JC), Nick Latimer (NL), Maxine Johnson (MJ)</p> <p>Observers Taryn Krause (TK) – National Collaborating centre for Chronic Conditions</p>	
Apologies:	<p>PDG Members Clare Gerada, Chris Record, Don Shenker,</p> <p>Co- Optees Peter Anderson</p>	
Authors	Patricia Mountain	
File Ref		
Version	Final 171008	
Audience	PDG members, NICE team, the public (via web publication)	

Item		Action
1	<p>Welcome, Introductions and Aims of the Meeting</p> <p>The Chair welcomed everyone to the first meeting. PDG members, NICE staff and contractors introduced themselves to the group and apologies were received.</p> <p>The Chair requested that any member biographies not yet received by NICE should be forwarded to Melinda Kay at NICE. All the members in the room had signed the Declaration of Interest forms and the Confidentiality Acknowledgement and Undertaking form. The Chair requested that those members who were not in attendance for this meeting, forward those documents through to Melinda Kay as soon as possible.</p> <p>The Chair outlined the objectives of the day:</p> <ul style="list-style-type: none"> • To continue to establish ways of working as a group • To understand the process of guidance development • To have a common understanding about the parameters of the guidance and the evidence to be considered at PDG meetings • To consider any implications from the evidence presented in this review for the development of guidance/draft recommendations • To improve awareness of the roles and responsibilities of other parts of NICE (e.g. communication) • To hear progress on the first effectiveness and cost effectiveness reviews relating to key questions identified in the scope • To discuss and feedback to the collaborating centre on how to improve and complete review <p>Apologies were received from PDG members - Clare Gerada, Chris Record, Don Shenker and from Co-optee – Peter Anderson</p>	
2	<p>Orientation on NICE process and methods</p> <p>Antony Morgan, Associate Director, gave a brief presentation to familiarise the PDG with the NICE guidance development process and provided a reminder of the key dates within the process.</p>	
3	<p>Communications</p> <p>Dylan Jones, Technical Lead for this guidance, gave a short presentation on behalf of the communications directorate on the role of the communications lead. The communications lead for this piece of guidance is Kristin O’Leary.</p>	
4	<p>Declarations of Interests</p> <p>Julian Lewis, Governance Manager, provided the committee with an overview of Declarations of Interests and the committee then proceeded to discuss any potential conflicts of interest. The Chair explained that the</p>	

	<p>verbal declarations of interest is a standing item on every agenda and is a matter of public record. All of the PDG present, the NICE team and SchARR then gave verbal declarations of interest specific to the topic, in addition to their written declarations that had been collected earlier.</p> <p>The Declarations of interest raised were;</p> <p>Paul Edmondson-Jones – potential personal non-pecuniary interest as a commissioner of services and member of National screening group on Alcohol</p> <p>Ian Treasure - potential personal non-pecuniary interest as a commissioner of services</p> <p>Paul McArdle – potential personal pecuniary interest -pharmaceutical company paid for his attendance at an international meeting and personal non pecuniary interest - published a randomised trial of group work which may potentially be used in the prevention of alcohol abuse</p> <p>Jim McCambridge – potential personal non-pecuniary interest – conclusions drawn in research studies that are in this area of guidance</p> <p>Trevor McCarthy- potential personal non- pecuniary interest - Presentations at conferences; development of <i>Model of care for Alcohol Misuse</i>, Review of effectiveness of treatment for alcohol problems</p> <p>Lynne Owens – potential personal non – pecuniary as a chair of nursing counsel on alcohol</p> <p>Eileen Kaner – potential personal non – pecuniary as someone who has developed screening tools and brief intervention material and drawn conclusions in this area in published review.</p> <p>Jane Benati – potential non personal pecuniary as someone with a research interest.</p> <p>Anne Ludbrook – potential personal non- pecuniary interest – as some of her staff received research grants from public sector sources. Also, personal non-pecuniary interest – research into alcohol related topics.</p>	
<p>5</p>	<p>Clinical Guidance Update</p> <p>Dylan Jones, technical lead for this guidance, gave a brief overview of the Clinical guidelines progress to date.</p> <p>A discussion was had on all the guidance currently being developed by NICE relating to alcohol disorders and where the public health scope sits within that; the public health scope being the prevention of alcohol disorders.</p> <p>An integrated care pathway that looks at the individual level to be produced.</p> <p>Discuss the inclusion of brief interventions for dependent drinkers.</p>	<p>NICE Team</p> <p>NICE Team</p>

<p>6</p>	<p>Overview of the effectiveness and cost effectiveness reviews</p> <p>Rachel Jackson from SchARR gave a presentation on the effectiveness review that they had undertaken. As an objective of this meeting was for the PDG to provide feedback to the collaborating centre on how to proceed to next stages of the review, a discussion then followed with both general ideas and suggestions specific to questions 4, 5, 6 and 7.</p>	
<p>7, 8</p>	<p>Discussion on the effectiveness and cost effectiveness reviews</p> <p>The Chair invited the PDG to discuss the evidence that had been presented to them and highlight some broad areas for recommendations. This was structured by looking at each of the questions individually.</p> <p><i>Question 4 – What are the key predictive factors that increase the risk of an individual misusing alcohol? When are individuals most vulnerable to alcohol misuse?</i></p> <p>The Committee made suggestions around the searching process.</p> <p>SchARR to reconsider the searching process for Q4 in light of the PDG’s comments</p> <p><i>Question 5 – Are alcohol screening questionnaires biochemical indicators and clinical indicators of alcohol misuse effective and cost effective ways of identifying adults and young people who currently misuse or are at risk of misusing alcohol?</i></p> <p>The Chair suggested that topic experts may be able to input to this question.</p> <p>NICE to ensure that all confidentiality and declaration of interest forms have been submitted so that all PDG members and co-optees can contribute to the discussion online</p> <p><i>Question 6 – Are brief interventions effective and cost effective in preventing hazardous and harmful drinking among adults and young people?</i></p> <p>The Committee gave direction to SchARR around the content of the narrative relating to ethnic breakdown, age and the substance of the intervention and who delivered it. It should also make clear in which settings we do and do not have information.</p> <p>By PDG 2 SchARR to amend the report in light of the committee’s</p>	<p>SchARR</p> <p>NICE Team</p> <p>SchARR</p>

	<p>comments.</p> <p><i>Question 7 - What are the key barriers and facilitators to helping adults and young people manage their drinking behaviour?</i></p> <p>The PDG made suggestions as to other types of evidence that it would be useful to consider in addition to qualitative research. This may necessitate the re-wording of the question to ensure that it accurately reflects the scope of the work being undertaken.</p> <p>SCHARR to ensure Question 7 is not solely qualitative based and to ensure the synthesis of the evidence takes the PDG’s comments into consideration. Q7 needs to address broader implementation issues and not just barriers and facilitators</p> <p>NICE Team to consider the re-wording of Question 7.</p> <p>Nick Latimer from SchHARR then continued the presentation with the economics section. The Committee made suggestions of other literature that may be more specifically relevant and thought that extra synthesis of the evidence is needed to allow the committee to make judgements based on the evidence.</p> <p>SCHARR to include new evidence and to address comments around the synthesis and overall conclusions.</p> <p>The Chair thanked SchHARR for their work on these questions and suggested that NICE should begin to draft recommendations from this work.</p> <p>The NICE team to draft early recommendations around brief interventions for the PDG to consider/amend. These should include the updating of the reviews being undertaken.</p>	<p>SCHARR</p> <p>NICE Team</p> <p>SCHARR</p> <p>NICE Team</p>
<p>9</p>	<p>Modelling Overview</p> <p>The Chair then explained to the PDG that, given the limited data available in the cost effectiveness review, it is normal for the collaborating centres to go on to develop economic models to ascertain the cost effectiveness of any recommendations that might be made. Therefore SchHARR was asked to outline an initial overview of their intended approach. The cost effectiveness of the recommendations needs to be finalised prior to the draft guidance going out to public consultation.</p> <p>Jim Chilcott from SchHARR gave brief presentation – <i>Overview of modelling – consumption to harm.</i></p>	
<p>10</p>	<p>Discussion on the modelling overview</p> <p>The Chair asked the PDG to discuss the outline of the economic model that had been presented to them.</p> <p>The Committee then discussed the presentation and gave direction to SchHARR regarding future searches that would be helpful. Issues around harm included; domestic violence, sexually transmitted diseases, mental</p>	

	<p>health.</p> <p>ScHARR to address the comments made by the PDG on potential areas for inclusion in the model.</p>	ScHARR
11	<p>Prevention review – input needed from the committee</p> <p>Jim Chilcott from ScHARR gave a short presentation on the development of the review on macro level interventions – <i>Modelling of prevention</i>.</p>	
12	<p>Discussion on the Prevention review – Committee input</p> <p>The Chair invited the PDG to give ScHARR their input on this piece of work.</p> <p>Areas for further work were highlighted;</p> <ul style="list-style-type: none"> • Potential information from Finland • Link between alcohol and sport sponsorship • Sociodemographics as a tool • Babor book to give insight into potential interventions for availability. • Econometric literature will prove useful. • Useful contacts were suggested <p>NICE team to produce a list of potential interventions to be looked at by ScHARR</p> <p>NICE team to add discussion on this topic to the next PDG agenda</p>	<p>NICE Team</p> <p>NICE Team</p>
13	<p>Next Steps</p> <p>Antony Morgan gave a short presentation on the next key dates from the project timeline. He explained that the process that NICE takes from the evidence to the writing of the recommendations must be defensible in terms of evidence and transparent in terms of process. This is so that the process is clearly auditable.</p> <p>Date of next meeting: Wednesday 16th October 2008, NICE Manchester office, City Tower, Manchester. Please not the change of venue. Meeting papers to be mailed: Monday 6th October 2008</p>	

14	Any Other Business The Chair thanked members and summarised the outcome of the day, with reference to the objectives stated at the start, in particular it was noted <ul style="list-style-type: none">• The Chair asked the NICE team to draft for discussion at next PDG preliminary recommendations, based on the evidence presented.• The Chair asked the NICE team to continue discussions with SCHARR on how to improve and complete review The Chair also requested that any outstanding Confidentiality Agreements, Declarations of interest and Biographies should be forward to Melinda Kay at NICE.	
Close	The Chair thanked all attendees and closed the meeting at 4pm.	